Treatment With Avacopan in Patients With Respiratory Tract Manifestations of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Objective The ADVOCATE trial demonstrated that treatment of active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) with avacopan was noninferior in achieving remission at week 26 and superior for sustained remission at week 52 compared with a prednisone taper. This analysis...
Saved in:
Main Authors: | Ulrich Specks, Robert F. Spiera, Lynn A. Fussner, Robert Lebovics, Sarah Bray, Rachel E. Gurlin, Darcy Trimpe, David R. W. Jayne, Peter A. Merkel, for the ADVOCATE Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | ACR Open Rheumatology |
Online Access: | https://doi.org/10.1002/acr2.11795 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan
by: Genri Tagami, et al.
Published: (2025-01-01) -
Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?
by: Saket Jha, et al.
Published: (2019-01-01) -
Comments on: Antineutrophil cytoplasmic autoantibody associated vasculitis-Clinical profile and outcomes
by: Rohini Handa
Published: (2018-01-01) -
Clinical Images: Propylthiouracil‐induced antineutrophil cytoplasmic antibody–associated vasculitis with aortic wall thickening
by: Sho Ishigaki, et al.
Published: (2025-01-01) -
Inflammatory Bowel Disease with Cytoplasmic-Staining Antineutrophil Cytoplasmic Antibody and Extensive Colitis
by: Hugh James Freeman
Published: (1998-01-01)